Table 3. Association between factors and the probability of poor clinical progression, at the end of the follow-up, in women with breast cancer (n=114). Campinas, SP, Brasil, 2013-2014.

Independent variables		Risk ratio*	Confidence interval		P -value
			L. L.	U. L.
Model 1
	Sleep quality (ref*: good)	0.78	0.27	2.29	.6538
	Presence of depression (ref: absence)	1.56	0.46	5.32	.4818
	Stage III (ref: stage I)	0.79	0.15	4.07	.7759
	Stage II (ref: stage I)	0.70	0.20	2.45	.5753
	HER2† status (ref: negative)	1.00	0.37	2.70	.9947
	Estrogen receptor (ref: negative)	1.54	0.37	6.44	.5515
	Progesterone receptor (ref: negative)	0.73	0.20	2.73	.6442
	Lymphatic invasion (ref: negative)	0.89	0.29	2.79	.8459
	HHS‡ score	0.94	0.86	1.02	.1396
	Tumor size	1.08	0.86	1.35	.5352
Model 2
	Sleep duration (ref : >6 and <9)	2.73	0.99	7.52	.0518
	Presence of depression (ref: absence)	1.22	0.35	4.33	.7565
	Stage III (ref: stage I)	0.76	0.15	3.90	.7438
	Stage II (ref: stage I)	0.73	0.21	2.56	.6169
	HER2† status (ref: negative)	1.08	0.39	3.00	.8768
	Estrogen receptor (ref: negative)	1.64	0.37	7.16	.5138
	Progesterone receptor (ref: negative)	0.80	0.20	3.20	.7502
	Lymphatic invasion (ref: negative)	0.70	0.22	2.20	.5422
	HHS‡ score	0.94	0.86	1.03	.2093
	Tumor size	1.06	0.84	1.33	.6444

*Ref: reference category

†HER2: Human Epidermal growth factor Receptor-type 2

‡HHS: Herth Hope Scale.